BiSTC Portfolio - Our Trials in More Detail

BiSTC trials portfolio  - our open trials are listed below.  Please follow the hyperlinks to the specific trials websites which contain further information about each study and who to contact. 

Also available as a PDF - BiSTC Open Trials

 ACCURE-UK-Logo_5

 

 

ACCURE UK:  The feasibility of undertaking Appendicectomy to impact upon the Clinical Course of UlceRativE Colitis - The ACCURE-UK Trial Feasibility study

Speciality: IBD

Chief Investigator: Mr Thomas Pinkney

Funded By: RfPB     Portfolio Study ID: 17515

Phase: Pilot/Feasibility

Initial Target Number of Patients: 48

 AdUP_Logo

AdUP:  A trial looking at a biological therapy to treat prostate cancer that has come back after radiotherapy and hormone therapy

Speciality: Prostate Cancer

Chief Investigator: Mr Prashant Patel

Funded By: MRC/Department of Health

Portfolio Study ID: 13599

Phase: Phase I     Initial Target Number of Patients: 15

 BASIL-2-Logo-Cropped-175x175

BASIL-2:  Multi-centre randomised controlled trial to compare the clinical and cost-effectiveness of a ‘vein bypass first’ with a ‘best endovascular treatment first’ revascularisation strategy for severe limb ischaemia due to infra-popliteal arterial disease

Speciality: Vascular

Chief Investigator: Professor Andrew Bradbury

Funded By: HTA     Portfolio Study ID: 16699

Phase: Phase III     Initial Target Number of Patients: 600

 BASIL-3-Logo_100x100

BASIL-3:  Multi-centre randomised controlled trial of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and plain balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to femoro-popliteal disease

Speciality: Vascular

Chief Investigator: Professor Andrew Bradbury

Funded By: NIHR    Portfolio Study ID: 19816

Phase: Phase III     Initial Target Number of Patients: 861

 BILCAP-Logo-100 pixels wide

BILCAP: A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer

Speciality: Upper GI

Chief Investigator: Professor John Primrose

Funded By: CRUK    Portfolio Study ID: 1473

Phase: Phase III     Initial Target Number of Patients: 410

 

BIOMEDE: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Speciality: Brain    Chief Investigator: Prof Darren Hargrave

Funded By:  CRUK     Portfolio Study ID: 33023

Phase:  Phase II   Initial Target Number of Patients: 80

 CompARE

compARE:  Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer

Speciality: Head and Neck

Chief Investigator: Professor Hisham Mehanna

Funded By: CRUK     Portfolio Study ID: 18621

Phase: Phase III     Initial Target Number of Patients: 650

 CReST-logo-2189x185

CReST:  The role of endoluminal stenting in the acute management of obstructing colorectal cancer

Speciality: Colorectal

Chief Investigator: Professor Jim Hill

Funded By: CRUK     Portfolio Study ID: 4708

Phase: Phase III     Initial Target Number of Patients: 500

DESKTOP

III

 

DESKTOP III:  A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer

Speciality: Ovarian Cancer

Chief Investigator: Professor David Luesley

Funded By: CTAAC     Portfolio Study ID: 11498

Phase: Phase III     Initial Target Number of Patients: 100

 ElaTION-Logo

ElaTION:  The Efficacy and Cost effectiveness of Real Time Ultrasound Elastography in The Investigation Of Thyroid Nodules and the diagnosis of thyroid cancer

Speciality: Head and Neck

Chief Investigator: Professor Hisham Mehanna

Funded By: HTA     Portfolio Study ID: 17373

Phase: Phase III     Initial Target Number of Patients: 1000

 ENDCaP-C-logo-jpeg

ENDCaP-C:  Enhanced Neoplasia Detection and Cancer Prevention in Chronic Colitis: A Multicentre test accuracy study

Speciality: IBD

Chief Investigator: Professor Tariq Iqbal

Funded By: NIHR EME      Portfolio Study ID: 17739

Phase: Phase III      Initial Target Number of Patients: 1000

 EPIVIN

EPIVIN:  A trial of Veregen cream for women with vulval intraepithelial neoplasia 

Speciality: Gynaecology Cancer

Chief Investigator: Professor David Luesley

Funded By: NIHR EME     Portfolio Study ID: 15759

Phase: Phase II     Initial Target Number of Patients: 56

 FEMME-logo

FEMME: A Randomised trial of treating Fibroids with either Embolisation or Myomectomy to Measure the Effect on quality of life, among women wishing to avoid hysterectomy: the FEMME study

Speciality: Reproductive Health

Chief Investigator: Professor Klim McPherson

Funded By: NIHR HTA     Portfolio Study ID: 11877

Phase: Phase III     Initial Target Number of Patients: 224

 FIAT-Logo

FIAT:  The Fistula-In-Ano Trial comparing Surgisis® anal fistula plug versus surgeon’s preference for transsphincteric fistula-in-ano

Speciality: Colorectal

Chief Investigator: Professor David Jayne

Funded By: HTA     Portfolio Study ID: 9592

Phase: Phase III     Initial Target Number of Patients: 500

 FOxTROT

FOxTROT:  Fluoropyrimidine, Oxaliplatin and Targeted-Receptor pre-Operative Therapy for patients with high-risk, operable colon cancer

Speciality: Colorectal

Chief Investigator: Professor Dion Morton

Funded By: CRUK     Portfolio Study ID: 3771

Phase: Phase III      Initial Target Number of Patients: 1050 


hymnlogosmall-Cropped-199x73

HYMN: A randomised, controlled, phase III trial comparing hyperthermia plus mitomycin (HM) to a second course of bacillus Calmette-Guérin (BCG) or standard therapy in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy

Speciality: Bladder Cancer

Chief Investigator: Professor John Kelly

Funded By: CRUK     Portfolio Study ID: 6553

Phase: Phase III       Initial Target Number of Patients: 242


IIH-WT-logo

IIH:WT:  is a randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of Idiopathic Intracranial Hypertension

Speciality: Neurological

Chief Investigator: Dr Alexandra Sinclair

Funded By: NIHR     Portfolio Study ID: 16025

Phase: Phase III      Initial Target Number of Patients: 60

 

NEO-EXCEL: Neoadjuvant trial of pre-operative exemestane or letrozole +/- celecoxib in the treatment of ER-positive postmenopausal early breast cancer

Speciality: Breast Cancer

Chief Investigator: Professor Daniel Rea

Funded By: CRUK     Portfolio Study ID: 1729

Phase: Phase III      Initial Target Number of Patients: 256

 LORIS%20Trial%20Logo%20Resized

LORIS:  A  trial comparing surgery with active monitoring for low risk DCIS

Speciality: Breast Cancer

Chief Investigator: Dr Matthew Wallis

Funded By: NIHR HTA     Portfolio Study ID: 16736

Phase: Phase III

Initial Target Number of Patients: 932

 PEGASUS-Logo 100 pixels wide

PEGASUS: A feasibility study and open pilot two-arm randomised controlled trial comparing Pressure Garment Therapy with no Pressure Garment Therapy for the prevention of abnormal scarring after burn injury (PEGASUS)

Speciality: Plastics

Chief Investitagor: Mr Naiem Moimen

Funded By: NIHR HTA     Portfolio Study ID: 17346

Phase: Pilot/Feasibility

Initial Target Number of Patients: 88

 ROCkeTS-Logo 100 pixels wide

ROCkeTS: Refining Ovarian Cancer Test Accuracy Scores: A test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer

Speciality: Gynaecology

Chief Investigator:  Mrs Sudha Sundar

Funded By: NIHR HTA     Portfolio Study ID: 17994

Phase: Diagnostic Test Accuracy Trial

Initial Target Number of Patients: 2450

 NewROCSSLogo

ROCSS:  Reinforcement of Closure of Stoma Site. A randomised controlled trial of reinforcement of closure of stoma site using a biological mesh

Speciality: Colorectal

Chief Investigator: Mr Aneel Bhangu

Funded By: LifeCell/RfPB     Portfolio Study ID: 13461

Phase: Phase III     Initial Target Number of Patients: 90

ROSCO

ROSCO: Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neo­adjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy

Speciality: Breast Cancer

Chief Investigator: Dr Daniel Rea

Funded By: CRUK/Celgene     Portfolio Study ID: 19069

Phase: Phase III     Initial Target Number of Patients: 1050

 SOCQER-2-Logo

SOCQER-2: Quality of Life Study in Patients Undergoing Surgery for Ovarian Cancer

Speciality: Gynaecology Cancer

Chief InvestigatorMrs Sudha Sundar

Funded By: NICE

Portfolio Study ID: 19553

Initial Target Number of Patients: 120

 TREC-logo

TREC:  Transanal Endoscopic Microsurgery (TEM) and Radiotheraphy in Early Rectal Cancer

Speciality: Colorectal     Chief Investigator: Mr Simon Bach

Funded By: CRUK     Portfolio Study ID: 7589

Phase: Phase III     Initial Target Number of Patients: 46

 STAR-TREC

STAR-TREC:  Can we save the rectum by watchful waiting or transanal surgery following (chemo)radiotherapy versus total mesorectal excision for early rectal cancer?

Speciality: Colorectal     Chief Investigator: Mr Simon Bach

Funded By: CRUK     Portfolio Study ID: 31203

Phase: Phase III     Initial Target Number of Patients: 120

 CReST2

CREST-2: ColoRectal Stenting Trial 2 - Uncovered vs covered endoluminal stenting in the acute management of obstructing colorectal cancer in the palliative setting.

Speciality: Colorectal     Chief Investigator: Professor James Hill

Funded By: NIHR HTA     Portfolio Study ID: 32120

Phase:  Phase III    Initial Target Number of Patients: 350

 VITTAL

VITTAL: Viability Testing and Transplantation of Marginal Livers

Speciality: Liver Transplantation     Chief Investigator: Professor Darius Mirza

 Funded By:  Wellcome Trust     Portfolio Study ID: 32299

 Phase:  Phase I/II    Initial Target Number of Patients: 23

 Wisteria Logo

WISTERIA: WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer

Speciality: Head and Neck     Chief Investigator: Professor Hisham Mehanna

Funded By:  NAC, ECMS/AZ Alliance     Portfolio Study ID: 32918

Phase:  Phase I    Initial Target Number of Patients: 42